Literature DB >> 12386497

Feasibility of public access to defibrillation.

Sherry Caffrey1.   

Abstract

Immediate defibrillation is the single most effective therapy to reverse ventricular fibrillation cardiac arrest today. The once physician-only skill of defibrillation has entered mainstream society and is saving the lives of many sudden cardiac arrest (SCA) victims in a variety of settings. The automated external defibrillator (AED) and the concept of public access defibrillation (PAD) are a result of collaborative efforts between the American Heart Association (AHA) and medical manufacturers. Today, airports, airlines, casinos, cruise ships, and other public venues have modernized their first aid kits to include an AED. The success of these programs has ignited a trend in public safety and subsequently marketed the worth of AEDs in the home. Although optimal placement of AEDs remains uncertain, PAD is showing great promise in reducing the death rate from SCA. The lay public, both trained and untrained, is emerging as the next level of emergency care responders able to use a defibrillator.

Entities:  

Mesh:

Year:  2002        PMID: 12386497     DOI: 10.1097/00075198-200206000-00001

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  2 in total

1.  European Resuscitation Council Guidelines for Resuscitation 2010 Section 2. Adult basic life support and use of automated external defibrillators.

Authors:  Rudolph W Koster; Michael A Baubin; Leo L Bossaert; Antonio Caballero; Pascal Cassan; Maaret Castrén; Cristina Granja; Anthony J Handley; Koenraad G Monsieurs; Gavin D Perkins; Violetta Raffay; Claudio Sandroni
Journal:  Resuscitation       Date:  2010-10       Impact factor: 5.262

2.  Performance of cardiopulmonary resuscitation feedback systems in a long-distance train with distributed traction.

Authors:  Digna M González-Otero; Sofía Ruiz de Gauna; Jesus Ruiz; Raquel Rivero; J J Gutierrez; Purificación Saiz; James K Russell
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.